On August 10, 2021 Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company reported that developing personalised medicine approaches to cancer, including targeted therapies, cell therapy enhancements and next generation CAR-T therapies (Press release, Prescient Therapeutics, AUG 10, 2021, View Source;utm_medium=rss&utm_campaign=90-seconds-with-steven-yatomi-clarke-from-prescient-therapeutics-asxptx [SID1234586274]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Encouraging progress through clinical trials of Prescient’s foundational assets PTX-100 and PTX-200 (with the PTX-100 trial progressing to expansion cohort last week following successful Phase 1b) and CAR-T safety and manufacturing milestone with OmniCAR.